NEWS - August 19, 2013
Research Featuring NeuroTrax Tests Selected as Editor’s Pick by MS Discovery Forum
Research using NeuroTrax tests to measure cognitive function in a large group of multiple sclerosis (MS) patients was selected as an Editor's Pick by the Executive Editor of the MS Discovery Forum (msdiscovery.org). The peer-reviewed article, published in the open-access PLoS One journal, reports on a study using NeuroTrax tests to model the relationship between cognitive function and disease duration in 1,500 patients with disease duration up to 30 years. In the study, Professor Anat Achiron of the Sheba Medical Center (Tel-Hashomer, Israel) and colleagues found that cognitive function measured by NeuroTrax tests differed from expected normal distribution beginning at five years from onset, most prominently in executive function. This is taken to suggest the existence of a therapeutic window during which patients may benefit from interventions to maintain cognitive health.
NeuroTrax provides research services to pharmaceutical and medical device companies as well as academic investigators in need of validated and standardized cognitive measures for their clinical trials. Services include data collection, data analysis, investigator training, customization, and software services.
Article on PLoS One
News Story on MS Discovery Forum